NCT02000700View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Canagliflozin 100 mg

One 100-mg tablet of canagliflozin orally administered daily for 14 days.

DRUG

Canagliflozin 50 mg

One 50-mg tablet of canagliflozin orally administered daily for 14 days.

DRUG

Canagliflozin 300 mg

One 300-mg tablet of canagliflozin orally administered daily for 14 days.

DRUG

Placebo

One matching placebo tablet orally administered at baseline phase.

Trial Locations (17)

Unknown

Little Rock

Los Angeles

Aurora

New Haven

Jacksonville

Indianapolis

Lenexa

Baltimore

Kansas City

Toledo

Pittsburgh

Houston

Salt Lake City

Campinas

Curitiba

Ribeirão Preto

São Paulo

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02000700 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter